Table 1 Relation between neurological manifestation and clinical data of β-thalassemia studied cases

Sex

 Male

55

66.3

28

33.7

0.383

 Female

48

71.6

19

29.4

Age

   years

59

100

0

0

< 0.001

 ≥ 16 years

44

48.4

47

51.6

BMI (kg/m²)

 Mean ± SD

19.02 ± 2.37

21.99 ± 2.63

0.000

 Duration of disease (years)

13.91 ± 3.30

17.58 ± 1.78

0.000

Mean ± SD

 Transfusion frequency

  timesyear

27

27.2

1

2.1

0.001

 ≥ 10 times/year

76

73.2

46

97.9

Splenomegaly

 No

17

40.5

25

59.5

0.005

 Yes

85

79.4

22

20.6

Splenectomy

 No

73

68.9

33

31.1

0.928

 Yes

30

68.2

14

31.8

Hepatomegaly

 No

59

47.6

65

52.4

0.005

 Yes

44

55.7

35

44.3

Iron chelation therapy

 Deferoxamine

29

63.0

17

37.0

0.135

 Deferasirox

55

82.1

12

17.9

 Deferiprone

16

72.7

6

27.3

 Combined

10

62.5

6

37.5